Literature DB >> 16432480

Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons.

Meghna Ramaswamy1, Caroline Sabin, Candice McDonald, Melvyn Smith, Chris Taylor, Anna Maria Geretti.   

Abstract

OBJECTIVE: The objective of this study was to determine herpes simplex virus type 2 (HSV-2) seroprevalence at HIV-1 diagnosis and seroincidence > or =1 year after HIV-1 diagnosis.
METHODS: HSV type-specific antibodies were detected by enzyme immunoassay.
RESULTS: The cohort comprised 850 adults diagnosed HIV-positive in 1986-2001 and followed for a median of 3 years. HSV-2 seroprevalence was 63% (95% confidence interval [CI], 60-66%) and was associated with female gender, heterosexual risk group, black ethnicity, and older age. HSV-2 seroincidence was 1.8 per 100 person-years (95% CI, 0.8-2.8) and was associated with other sexually transmitted diseases, including human papilloma virus infection (P = 0.005) and gonorrhea (P = 0.05). A diagnosis of genital herpes was made in 21% HSV-2-seropositive persons and was more likely in those who tested HIV-positive before 1997 (adjusted odds ratio, 5.11; 95% CI, 3.28-7.98; P = 0.0001).
CONCLUSIONS: Results confirm the epidemiologic association between HIV-1 and HSV-2. HSV-2 seroconversion was a marker of high-risk sexual behavior. The likelihood of developing symptoms of genital herpes declined from 1997 onward.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432480     DOI: 10.1097/01.olq.0000187211.61052.c7

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  12 in total

1.  Herpes simplex virus type 2 seroprevalence and incidence in acute and chronic HIV-1 infection.

Authors:  M Lagnese; E S Daar; P Christenson; G Rieg
Journal:  Int J STD AIDS       Date:  2011-07-08       Impact factor: 1.359

2.  Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort.

Authors:  Brooke E Hoots; Michael G Hudgens; Stephen R Cole; Caroline C King; Robert S Klein; Kenneth H Mayer; Anne M Rompalo; Jack D Sobel; Denise J Jamieson; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2011-03-03       Impact factor: 4.897

3.  Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?

Authors:  Darrell H S Tan; Rupert Kaul; Sharon Walsmley
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 4.  Herpes simplex virus type 2: epidemiology and management options in developing countries.

Authors:  G Paz-Bailey; M Ramaswamy; S J Hawkes; A M Geretti
Journal:  Sex Transm Infect       Date:  2006-11-10       Impact factor: 3.519

5.  Evaluation of three multiplex flow immunoassays compared to an enzyme immunoassay for the detection and differentiation of IgG class antibodies to herpes simplex virus types 1 and 2.

Authors:  M J Binnicker; D J Jespersen; J A Harring
Journal:  Clin Vaccine Immunol       Date:  2009-12-09

6.  Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels.

Authors:  Edward R Cachay; Simon D W Frost; Art F Y Poon; David Looney; Sherry M Rostami; Mary E Pacold; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

7.  Severe Primary HSV-2 in a Perinatal HIV-Infected Woman with Advanced Immunosuppression.

Authors:  Lana Lee; Allison Agwu; Nancy Hutton
Journal:  Case Rep Med       Date:  2012-08-01

8.  Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Beatriz Grinsztejn; Pedro Cahn; Sharon L Walmsley
Journal:  Trials       Date:  2010-11-24       Impact factor: 2.279

Review 9.  Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Authors:  Darrell Hoi-San Tan; Kellie Murphy; Prakesh Shah; Sharon Lynn Walmsley
Journal:  BMC Infect Dis       Date:  2013-10-28       Impact factor: 3.090

10.  Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.

Authors:  Ian McGowan; Ross D Cranston; Kenneth H Mayer; Irma Febo; Kathryn Duffill; Aaron Siegel; Jarret C Engstrom; Alexyi Nikiforov; Seo-Young Park; Rhonda M Brand; Cindy Jacobson; Rebecca Giguere; Curtis Dolezal; Timothy Frasca; Cheng-Shiun Leu; Jill L Schwartz; Alex Carballo-Diéguez
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.